Ruiyuan Xu

2.0k total citations · 2 hit papers
23 papers, 1.2k citations indexed

About

Ruiyuan Xu is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Ruiyuan Xu has authored 23 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 12 papers in Molecular Biology and 8 papers in Cancer Research. Recurrent topics in Ruiyuan Xu's work include Pancreatic and Hepatic Oncology Research (14 papers), Epigenetics and DNA Methylation (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Ruiyuan Xu is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Epigenetics and DNA Methylation (5 papers) and Cancer, Hypoxia, and Metabolism (4 papers). Ruiyuan Xu collaborates with scholars based in China. Ruiyuan Xu's co-authors include Rexiati Ruze, Jianlu Song, Xinpeng Yin, Lei You, Jinshou Yang, Bo Ren, Yuan Chen, Chengcheng Wang, Yupei Zhao and Qiang Xu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Biochemical and Biophysical Research Communications.

In The Last Decade

Ruiyuan Xu

23 papers receiving 1.2k citations

Hit Papers

Obesity and type 2 diabet... 2021 2026 2022 2024 2023 2021 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments
    2023 351 citations Rexiati Ruze, Jianlu Song et al. Frontiers in Endocrinology profile →
  2. Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review
    2021 214 citations Jinshou Yang, Ruiyuan Xu et al. Cancer Communications profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ruiyuan Xu China 14 544 324 296 176 141 23 1.2k
Mirco Zucchelli Italy 20 681 1.3× 192 0.6× 312 1.1× 166 0.9× 137 1.0× 38 1.5k
Susen Becker Germany 21 554 1.0× 202 0.6× 147 0.5× 175 1.0× 140 1.0× 36 1.2k
Liu Gao-lin China 22 610 1.1× 163 0.5× 241 0.8× 253 1.4× 155 1.1× 56 1.4k
Xuansheng Ding China 23 727 1.3× 157 0.5× 350 1.2× 111 0.6× 152 1.1× 89 1.6k
Fang Fang China 22 999 1.8× 264 0.8× 315 1.1× 87 0.5× 157 1.1× 82 1.6k
Yin Cai China 23 648 1.2× 118 0.4× 214 0.7× 216 1.2× 212 1.5× 84 1.4k
Xu Zhou China 17 396 0.7× 150 0.5× 173 0.6× 167 0.9× 180 1.3× 91 1.2k
Stephan Winnik Switzerland 17 542 1.0× 177 0.5× 145 0.5× 316 1.8× 220 1.6× 46 1.7k
Chao Zheng China 21 454 0.8× 151 0.5× 130 0.4× 146 0.8× 139 1.0× 80 1.3k
Jessica A. Bonzo United States 20 655 1.2× 248 0.8× 196 0.7× 120 0.7× 157 1.1× 32 1.3k

Countries citing papers authored by Ruiyuan Xu

Since Specialization
Citations

This map shows the geographic impact of Ruiyuan Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruiyuan Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruiyuan Xu more than expected).

Fields of papers citing papers by Ruiyuan Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruiyuan Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruiyuan Xu. The network helps show where Ruiyuan Xu may publish in the future.

Co-authorship network of co-authors of Ruiyuan Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Ruiyuan Xu. A scholar is included among the top collaborators of Ruiyuan Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruiyuan Xu. Ruiyuan Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Yuan, et al.. (2025). Pancreatic endocrine and exocrine signaling and crosstalk in physiological and pathological status. Signal Transduction and Targeted Therapy. 10(1). 39–39. 11 indexed citations
2.
Ruze, Rexiati, et al.. (2024). Enhanced cytokine signaling and ferroptosis defense interplay initiates obesity-associated pancreatic ductal adenocarcinoma. Cancer Letters. 601. 217162–217162. 8 indexed citations
3.
Chen, Yuan, et al.. (2024). Cancer-Associated Endocrine Cells Participate in Pancreatic Carcinogenesis. Gastroenterology. 167(6). 1167–1182.e23. 3 indexed citations
4.
Ruze, Rexiati, Jianlu Song, Xinpeng Yin, et al.. (2023). Mechanisms of obesity- and diabetes mellitus-related pancreatic carcinogenesis: a comprehensive and systematic review. Signal Transduction and Targeted Therapy. 8(1). 139–139. 48 indexed citations
5.
Song, Jianlu, Ruiyuan Xu, Hui Zhang, et al.. (2023). Cell-in-Cell–Mediated Entosis Reveals a Progressive Mechanism in Pancreatic Cancer. Gastroenterology. 165(6). 1505–1521.e20. 14 indexed citations
6.
Ruze, Rexiati, Jianlu Song, Yuan Chen, et al.. (2023). Obesity and type 2 diabetes mellitus: connections in epidemiology, pathogenesis, and treatments. Frontiers in Endocrinology. 14. 1161521–1161521. 351 indexed citations breakdown →
7.
Xu, Ruiyuan, Jianlu Song, Rexiati Ruze, et al.. (2023). SQLE promotes pancreatic cancer growth by attenuating ER stress and activating lipid rafts-regulated Src/PI3K/Akt signaling pathway. Cell Death and Disease. 14(8). 497–497. 43 indexed citations
8.
Yin, Xinpeng, Ruiyuan Xu, Jianlu Song, et al.. (2022). Lipid metabolism in pancreatic cancer: emerging roles and potential targets. Cancer Communications. 42(12). 1234–1256. 73 indexed citations
9.
Wang, Chengcheng, Ruiyuan Xu, Jianlu Song, et al.. (2022). Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis. Frontiers in Oncology. 12. 1004850–1004850. 3 indexed citations
10.
Yin, Xinpeng, Yuan Chen, Rexiati Ruze, et al.. (2022). The evolving view of thermogenic fat and its implications in cancer and metabolic diseases. Signal Transduction and Targeted Therapy. 7(1). 324–324. 36 indexed citations
11.
Ruze, Rexiati, Yuan Chen, Ruiyuan Xu, et al.. (2022). Obesity, diabetes mellitus, and pancreatic carcinogenesis: Correlations, prevention, and diagnostic implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer. 1878(1). 188844–188844. 13 indexed citations
12.
13.
Yang, Jinshou, Ruiyuan Xu, Chengcheng Wang, et al.. (2021). Early screening and diagnosis strategies of pancreatic cancer: a comprehensive review. Cancer Communications. 41(12). 1257–1274. 214 indexed citations breakdown →
14.
Chen, Yuan, Ruiyuan Xu, Rexiati Ruze, et al.. (2021). Construction of a prognostic model with histone modification-related genes and identification of potential drugs in pancreatic cancer. Cancer Cell International. 21(1). 291–291. 8 indexed citations
15.
Ren, Bo, Jinshou Yang, Chengcheng Wang, et al.. (2021). High-resolution Hi-C maps highlight multiscale 3D epigenome reprogramming during pancreatic cancer metastasis. Journal of Hematology & Oncology. 14(1). 120–120. 45 indexed citations
16.
Chen, Yuan, Bo Ren, Jinshou Yang, et al.. (2020). The role of histone methylation in the development of digestive cancers: a potential direction for cancer management. Signal Transduction and Targeted Therapy. 5(1). 143–143. 95 indexed citations
17.
Xu, Ruiyuan, Jinshou Yang, Bo Ren, et al.. (2020). Reprogramming of Amino Acid Metabolism in Pancreatic Cancer: Recent Advances and Therapeutic Strategies. Frontiers in Oncology. 10. 572722–572722. 54 indexed citations
18.
Xu, Ruiyuan, Xiaoran Li, Lin Xiao, et al.. (2019). DJ-1 overexpression confers the multidrug resistance phenotype to SGC7901 cells by upregulating P-gp and Bcl-2. Biochemical and Biophysical Research Communications. 519(1). 73–80. 13 indexed citations
19.
Xu, Ruiyuan, et al.. (2019). Resveratrol attenuates myocardial hypoxia/reoxygenation-induced cell apoptosis through DJ-1-mediated SIRT1-p53 pathway. Biochemical and Biophysical Research Communications. 514(2). 401–406. 32 indexed citations
20.
Xu, Ruiyuan & Jieping Hu. (2019). The role of JNK in prostate cancer progression and therapeutic strategies. Biomedicine & Pharmacotherapy. 121. 109679–109679. 72 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mirco Zucchelli Breakdown of academic impact, for papers by Susen Becker Breakdown of academic impact, for papers by Liu Gao-lin Breakdown of academic impact, for papers by Xuansheng Ding Breakdown of academic impact, for papers by Fang Fang Breakdown of academic impact, for papers by Yin Cai Breakdown of academic impact, for papers by Xu Zhou Breakdown of academic impact, for papers by Stephan Winnik Breakdown of academic impact, for papers by Chao Zheng Breakdown of academic impact, for papers by Jessica A. Bonzo
Rankless by CCL
2026